NCT02146651View on ClinicalTrials.gov

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions
Diabetes Mellitus Type 1
Interventions
DRUG

BioChaperone insulin lispro 0.2U/Kg

Single dose of 0.2U/Kg body weight injected subcutaneously

DRUG

BioChaperone insulin lispro 0.1U/Kg

Single dose of 0.1U/Kg body weight injected subcutaneously

DRUG

BioChaperone insulin lispro 0.4U/Kg

Single dose of 0.4U/Kg body weight injected subcutaneously

DRUG

Humalog®

Single dose of 0.2U/Kg body weight injected subcutaneously

Trial Locations (1)

41460

Profil Institut für stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

Adocia
All Listed Sponsors
lead

Adocia

INDUSTRY

NCT02146651 - A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes | Biotech Hunter | Biotech Hunter